Future Science Group
Browse
Supplemental Figures.docx (957.94 kB)

Supplementary Figures – Real-world treatment patterns and overallsurvival in BRAF-mutant melanoma patientstreated with immunotherapy or targetedtherapy

Download (957.94 kB)
figure
posted on 2022-04-20, 09:23 authored by Figshare Future Science GroupFigshare Future Science Group, Michael B Atkins, Cristina Julian, Matthew H Secrest, Janet Lee, Ana M Abajo-Guijarro, Edward McKenna

  

Supplemental Figure 1. Kaplan-Meier Estimates of Overall Survival (OS) in Patients With Advanced BRAF-Mt Melanoma Receiving 1L Treatment With CPI (ipilimumab/nivolumab) or TT.

  

Supplemental Figure 2. Kaplan-Meier estimates of Overall Survival (OS) in Patients With Advanced BRAF-Mt Melanoma Receiving 1L Treatment With CPI (ipilimumab/nivolumab) or TT weighted by IPTW.

Funding

F Hoffmann-La Roche Ltd. and Genentech, Inc

History